Email Updates

Search form

You are here

AVAC in the News

  • In the next few months, said Mitchell Warren, executive director of AVAC, an advocacy group for AIDS prevention, “we’re going to see a cascade of results” from trials of what is called “oral pre-exposure prophylaxis,” or “oral prep” for short. In them, men and women who are not infected with the AIDS virus but who regularly engage in high-risk sex, like anal sex without condoms or sex for money with strangers, take a daily dose of one or two of the antiretroviral drugs normally taken by infected people.

    November 8, 2010
    New York Times
  • Mitchell Warren, executive director of global advocacy organisation AVAC, said: "Not only is South Africa at the forefront of testing individual approaches but it is leading the development of combination prevention, which is clearly the only way to truly end the epidemic."

    May 26, 2010
    Times (South Africa)
  • This year, for the first time, we mark the Day with hope based on evidence from a trial in humans that shows that an AIDS vaccine is possible.

    May 17, 2010
    Huffington Post
  • The microbicides field has undoubtedly moved and shifted a lot in the past decade. Now, with first generation microbicides candidate products up and gone, antiretroviral treatment (ART)-drug based microbicides in spotlight, and only three major microbicides efficacy studies remaining, the need to lobby for increased funding of microbicides research and development, was never so compelling.

    May 14, 2010
    Citizen News Service
  • Gilead Sciences Inc. may learn this year whether its drugs for treating HIV can also stop people from catching the virus in the first place. The approach may help curb the AIDS pandemic in poor countries and bring Gilead $1 billion a year in additional U.S. sales, said Josh Schimmer, an analyst at Leerink Swann & Co. in Boston. Most investors aren’t alert to the potential benefit, he said. Researchers are compiling the first data from 10 trials involving more than 20,000 people, and initial results may be available in July.

    April 1, 2010
    Bloomberg
  • Researchers said the failure of the microbicide gels in a trial in South Africa, Zambia, Uganda and Tanzania was the last nail in the coffin for this type of prevention method.

    December 15, 2009
    New York Times
  • An antimicrobial gel tested as a method to curb the spread of HIV just proved ineffective in a major human study.

    December 14, 2009
    NPR
  • A decade of increasing funding for HIV programs - in prevention, treatment and research - is paying off. Ironically, though, this good news comes at the same time that the global economic crisis and political arguments threaten the future of HIV funding.

    November 30, 2009
    Huffington Post
  • The modest protective effect of the HIV vaccine combination used in the Thai vaccine trial announced last month is statistically significant and not the result of massaging the statistics to produce a positive result, study investigators said at the AIDS Vaccine 2009 conference in Paris today.

    October 20, 2009
    aidsmap
  • The fog around the largest AIDS vaccine study ever conducted began to lift today, as Thai and U.S. researchers for the first time publicly presented a detailed analysis of their data to over 1000 scientists gathered here at an annual meeting.

    October 20, 2009
    Science Insider

Pages